Drug-resistant tuberculosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
==Multiple Drug-Resistant (MDR) Tuberculosis== | ==Multiple Drug-Resistant (MDR) Tuberculosis== | ||
MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs. | *MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs. | ||
*Medical treatment for MDR-TB consists of at least 4 drugs that have shown effectiveness against MDR. | |||
{| | {| | ||
| valign=top | | | valign=top | | ||
| Line 34: | Line 34: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF| | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|MDR-TB Adults}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 1</u>''' <br> | ||
▸ ''' Pyrazinamide''' <br> OR <br> ▸ '''Ethambutol ''' <br> OR <br> ▸ '''Rifabutin''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 2</u>''' <br> | |||
▸ '''Kanamycin'''<br> OR <br> ▸ '''Amikacin'''<br> OR <br> ▸ '''Capreomycin'''<br> OR <br> ▸ '''Streptomycin'''<br> OR <br> | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 3</u>''' <br> | |||
▸ ''''''<br> OR <br> ▸ ''''''<br> OR <br> ▸ ''''''<br> OR <br> ▸ ''''''<br> OR <br> | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 4</u>''' <br> | |||
▸ ''''''<br> OR <br> ▸ ''''''<br> OR <br> ▸ ''''''<br> OR <br> ▸ ''''''<br> OR <br> | |||
|- | |- | ||
|} | |} | ||
| Line 45: | Line 61: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF| | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|MDR-TB Children}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | ||
Revision as of 15:15, 17 September 2014
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Drug-resistant tuberculosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Drug-resistant tuberculosis medical therapy |
|
Risk calculators and risk factors for Drug-resistant tuberculosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
Multiple Drug-Resistant (MDR) Tuberculosis
- MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs.
- Medical treatment for MDR-TB consists of at least 4 drugs that have shown effectiveness against MDR.
|
MDR Tuberculosis ▸ Adults ▸ Children |
|
Extensively Drug-Resistant XDR Tuberculosis
XDR-TB is defined as resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables (amikacin, capreomycin, and kanamycin).
|
XDR Tuberculosis ▸ Adults ▸ Children |
|